Put companies on watchlist
Liquidia
ISIN: US53635D2027
WKN: A2JRNS
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Liquidia · ISIN: US53635D2027 · PR Newswire (ID: 20240828DC91596)
28 August 2024 10:00PM

Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings


 NEW YORK, Aug. 28, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Technologies, Inc. ("Liquidia" or "the Company") (NASDAQ: LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LQDA.

Investigation Details

On August 19, 2024, Liquidia issued a press release announcing that "the U.S. Food and Drug Administration (FDA) has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)" but "must await the expiration of regulatory exclusivity of a competing product before final approval can be granted." On this news, Liquidia's stock price fell $4.32 per share, or 30.62%, to close at $9.79 per share on August 19, 2024.

What's Next?

If you are aware of any facts relating to this investigation or purchased Liquidia securities, you can assist this investigation by visiting the firm's site: bgandg.com/LQDA. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660 | info@bgandg.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-against-liquidia-technologies-inc-lqda-and-encourages-shareholders-to-seek-compensation-for-alleged-wrongdoings-302231649.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

Visual performance / price development - Liquidia
Smart analysis and research tools can be found here.
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2025
PR Newswire
Contact:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942